MDB · Investment summary · as of 30 July 2026
Priced close to what the business has demonstrated
Business type: Inflection · scaling but economically observable
The operating path required by the price could not be established.
At $325.88, MDB requires a 19% five-year revenue growth rate to justify its enterprise value — less than the business already delivers, at 24%.
The conditions that would settle the disagreement are dated to July 2026.
The value rests on an exit multiple of 5.1x and a terminal operating margin of 17%. Move any one of them materially and the conclusion moves with it, which is why the required-versus-demonstrated test above carries more weight here than the point value.
The strongest argument against this view: net ARR expansion decays to 100% — no net expansion from the installed base at all — and stays there, so revenue growth converges on new-customer acquisition alone (roughly 8%) and plateaus near $2.9bn.
| Question | Evidence-based conclusion |
|---|---|
| What drives the business? | Not determined — the operating driver is not stated in one place |
| What do we forecast? | Revenue growth of 24% demonstrated; a terminal operating margin of 17%; an exit multiple of 5.1x. |
| What does Street forecast? | Not determined — no consensus estimates are joined to this record |
| Where do we differ? | On revenue growth, the difference between what the price requires and what the business has demonstrated is +4.2 percentage points. |
| What is it worth? | Twelve-month target $445.38, +37% from the struck price. Scenario-weighted expected return net of costs +36.7%. |
| Why now? | The first dated test of the thesis falls on 31 July 2026. |
| Date or window | Event | Thesis confirmed if | Thesis weakened or refuted if |
|---|---|---|---|
| 31 July 2026 | Net ARR expansion rate, on MongoDB's own disclosed definition — ARR… | Net ARR expansion rate at or above 115% in any quarterly filing, and at or at or above 118% in two consecutive… | Net ARR expansion rate below 115% in any quarterly filing, OR at or below 118% in two consecutive quarterly filings. |
| every 10-Q and 10-K; first tested on the Q2 FY2027 10-Q, expected late August 2026 | Atlas revenue, computed as the disclosed Atlas share of total revenue… | Year-over-year Atlas revenue growth at or above 18% in any fiscal quarter. | Year-over-year Atlas revenue growth below 18% in any fiscal quarter. |
| every 10-Q and 10-K; first tested on the Q2 FY2027 10-Q (late August 2026), confirmed or cleared on the Q3 FY2027 10-Q (early December 2026) | Trailing-twelve-month GAAP operating margin, current TTM window… | TTM GAAP operating margin improves by at least 2.0pp year over year in two consecutive quarterly filings. | TTM GAAP operating margin improves by less than 2.0pp year over year in two consecutive quarterly filings. |
| every 10-Q and 10-K; first tested on the Q2 FY2027 10-Q, expected late August 2026, and on current trend first at risk around FY2029 | Trailing-twelve-month GAAP gross profit over TTM revenue | TTM gross margin at or above 69.0%. | TTM gross margin below 69.0%. |
Net ARR expansion decays to 100% — no net expansion from the installed base at all — and stays there, so revenue growth converges on new-customer acquisition alone (roughly 8%) and plateaus near $2.9bn. In that fundamental state MongoDB is a high-gross-margin, low-growth, thin-GAAP-margin infrastructure business, which its own growth-matched cohort prices at 1.9-3.5x EV/Sales (NICE 1.89x, OTEX 2.13x, PEGA 2.64x, ESTC 3.38x). At 3.5x — the top of that range, credited for the 72% gross margin and the net cash — EV $10,150m plus $2,430.6m net cash = $12,581m over 80.504m shares = $156 per share, a 52% permanent loss from $325.88.
Estimated probability 15%, against the 25% level at which the position would be resized. It sits within that level.
Falsifiable and fundamental — not one of them is a price condition.
On approach to the $445.38 target the case is reviewed rather than added to; a target reached is a reason to re-examine the position, not to hold it by default. The position is trimmed once forward expected return falls below 0% net of costs, because the capital has a better use elsewhere in the book.
| Criteria | Status | Investment meaning |
|---|---|---|
| Quality | Met | Is the business worth owning under its declared economic type? |
| Valuation | Not determined | Is the operating path required by today's price achievable? Not established on the evidence on file. |
| Liquidity | Met | Can the intended position be built and exited in the right vehicle? |
| Downside | Met | Net ARR expansion decays to 100% — no net expansion from the installed base at all — and stays there, so revenue growth converges on new-customer acquisition alone (roughly 8%) and plateaus near $2.9bn. |
| Momentum | Not determined | Does price action support or complicate entry timing? Not established on the evidence on file. |
| Catalyst | Met | Is there a dated event that resolves the disagreement? |
| Consensus | Not determined | Is the house-versus-Street disagreement identified and quantified? Not established on the evidence on file. |
Quality, valuation and liquidity can prevent a position on their own. The remaining four inform timing, sizing and monitoring, and never reject an investment by themselves.
The strongest case for mispricing is that the business already delivers +4.2 percentage points more growth than the price requires. The most important unresolved uncertainty is whether the operating path today's price requires is achievable; the evidence does not settle it. The next evidence that should change the portfolio decision is the test dated 31 July 2026, or a daily close below $270.66, which forces an immediate review.